Navigation Links
Nature Methods study: Using light to control cell clustering
Date:2/12/2013

Troy, N.Y. A new study from engineers at Rensselaer Polytechnic Institute and the University of California, Berkeley, pairs light and genetics to give researchers a powerful new tool for manipulating cells. Results of the study, published in the journal Nature Methods, show how blue light can be used as a switch to prompt targeted proteins to accumulate into large clusters.

This process of clustering, or oligomerization, is commonly employed by nature to turn on or turn off specific signaling pathways used in cells' complex system of communications. The new study details how this process can be replicated with great precision, giving researchers new capabilities to control and influence the process of oligomerization and cell signaling.

Ravi Kane, the P.K. Lashmet Professor in the Howard P. Isermann Department of Chemical and Biological Engineering and faculty member of the Center for Biotechnology and Interdisciplinary Studies at Rensselaer, co-led the study with Professor David Schaffer of the Department of Chemical Engineering at the UC Berkeley. This study was made possible with support from the U.S. Department of Energy's Office of Basic Energy Science.

"Our study shows a new use for using energy, in this case light, as a tool to understand and control cellular function. In this study, we demonstrated a new method for turning specific cell signaling pathways on and off with spatial and temporal precision, and use this to help better understand the dynamics of the pathway. At the same time, our technique can be used to control certain cell functions," Kane and Schaffer said.

Looking ahead, Kane said, it is possible the new process may also one day be able to help optimize cellular function and produce products of interest to energy production, such as biofuels.

Results of the study, titled "Optogenetic protein clustering and signaling activation in mammalian cells," were published online last wee
'/>"/>

Contact: Michael mullaney
mullam@rpi.edu
518-276-6161
Rensselaer Polytechnic Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
2. Epigenetic signatures direct the repair potential of reprogrammed cells
3. Nature: Video reveals wave character of particles
4. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
5. Stoneflies mapped across Ohio, with implications for water quality and nature conservation
6. Gene signature helps identify risk of relapse in lung cancer patients
7. Natures billion-year-old battery key to storing energy
8. Can natures beauty lift citizens from poverty?
9. Biosignatures distinguish between tuberculosis and sarcoidosis
10. Nature: Microscope looks into cells of living fish
11. Nature or nurture? It may depend on where you live
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nature Methods study: Using light to control cell clustering
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... IOF and ESCEO will be staging the ... largest bone meeting in Europe, to be held ... the pre-registration deadline of March 7, 2011 fast ... registration to the 1st IOF-ESCEO Pre-Clinical Symposium (from ...
... Scientists have published results that will forever change the ... replication and the prevention of DNA damage. ... to many problems including cancers. Researchers, funded by the ... Wellcome Trust and working at The University of Nottingham, ...
... Chase, MDA recent study accepted for publication in ... for the first time that maternal fructose intake during ... endocrinology. Fructose is a simple sugar found naturally ... dietary fructose, particularly due to calorically sweetened beverages, are ...
Cached Biology News:8 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2Collisions of protein machines cause DNA replication derailment 2Maternal fructose intake impacts female and male fetuses differently 2
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... safety and efficacy of Albuferon administered every four weeks in ... hepatitis C - , , ROCKVILLE, Md., June 19 ... today announced that Novartis has completed enrollment and initial dosing ... and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination ...
... Has Tentative FDA Approval and Expects Final Approval Shortly -- ... Inc. (NYSE: HSP ), the world leader in ... for the District of New Jersey has granted summary judgment ... chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from ...
... WalkMS Participants - , , NEW YORK, June ... family, and other people living with multiple sclerosis, Saatchi & ... component of the "I Walk Because" program. The site ... social media applications. , , The site, ...
Cached Biology Technology:Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3I Walk Because Program Gives Consumers a Voice 2I Walk Because Program Gives Consumers a Voice 3
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
...
Biology Products: